| Autor: |
Eren, Erden, Hunt, Jack F. V., Shardell, Michelle, Chawla, Sahil, Tran, Joyce, Gu, Jeffrey, Vogt, Nick M., Johnson, Sterling C., Bendlin, Barbara B., Kapogiannis, Dimitrios |
| Zdroj: |
Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Sep2020, Vol. 16 Issue 9, p1293-1304, 12p |
| Abstrakt: |
Introduction: Neuronal extracellular vesicle (nEV) tau and insulin signaling biomarkers may detect preclinical Alzheimer's disease and age‐associated cognitive decline. Methods: This case‐control study used repeated serum samples from 73 cognitively declining and 73 stable Wisconsin Registry for Alzheimer's Prevention participants (62.4 ± 6.3 years old). We immunocaptured nEVs; measured tau and insulin signaling biomarkers; and examined biomarker differences by group, their performance in group classification in training and test datasets (97, 49 individuals, respectively), and whether they predict cognitive performance change. Results: Declining compared to stable individuals showed higher baseline total, p231‐, and p181‐tau with older age and higher annualized change for p‐IR and p‐IGF‐1R. Combining biomarkers classified decliners with 94% area under the curve (AUC), 86.0% sensitivity and 86.7% specificity, in training data, and 75% AUC, 71.4% sensitivity, and 77.3% specificity, in test data. Insulin biomarkers predicted cognitive performance change prospectively. Discussion: Combining nEV biomarkers can identify individuals with age‐associated cognitive decline. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
